ALZ-NET

Study Purpose

The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is looking to collect information from individuals who are evaluated for or receive treatment with novel (or new) FDA-approved therapies for Alzheimer’s disease (AD). A novel FDA approved therapy for AD is a medication that has been approved by the FDA since 2021 and has Alzheimer’s disease listed as an indication with the prescribing instructions. ALZ-NET will follow and record information about people’s health, safety, brain scans, and long-term health outcomes during their regular memory care.

Who Can Participate

Age: 18 years and older